Device Trial Radar · NCT06891898
The iLet Experience Study
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,875
Planned (sponsor's estimate)
Start
May 1, 2024
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Beta Bionics, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- The Scripps Research Institute
- First posted
- Mar 24, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months follow-up.
Conditions
- Type 1 Diabetes
Interventions
iLet Dosing Decision SoftwareDevice
Interoperable alternate glycemic controller
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severe Hypoglycemia/cognitive impairmentTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beta Bionics
Irvine, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.